公开(公告)号：EP2991982A1

公开(公告)日：2016-03-09

申请号：EP14792173.8

申请日：2014-04-29

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-Mo ,  CHOI, Hojin ,  KIM, Dohoon ,  KIM, Soyoung ,  HA, Nina ,  LIM, Hyojin ,  KO, Eunhee ,  YOON, Seongae ,  BAE, Daekwon

IPC分类号： C07D413/12 ,  A61K31/5377 ,  A61P35/00 ,  A61P29/00

CPC分类号： C07D231/56 ,  C07D207/08 ,  C07D207/10 ,  C07D209/08 ,  C07D209/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/52 ,  C07D213/40 ,  C07D213/74 ,  C07D213/75 ,  C07D215/12 ,  C07D239/26 ,  C07D239/42 ,  C07D265/30 ,  C07D295/215 ,  C07D309/08 ,  C07D309/10 ,  C07D317/58 ,  C07D319/18 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.

公开(公告)号：EP3089977A1

公开(公告)日：2016-11-09

申请号：EP15733170.3

申请日：2015-01-02

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-Mo ,  KIM, Dohoon ,  BAE, Miseon ,  CHOI, Youngil ,  HA, Nina

IPC分类号： C07D413/06 ,  A61K31/5377 ,  A61P37/00 ,  A61P3/10

CPC分类号： C07D209/20 ,  C07D209/10 ,  C07D401/06 ,  C07D401/08 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provides a novel indole derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The compound according to the present invention can selectively inhibit histone deacetylase (HDAC), and thus can be used to effectively treat a disease associated with histone deacetylase (HDAC) activity.

公开(公告)号：EP2991982B1

公开(公告)日：2018-08-15

申请号：EP14792173.8

申请日：2014-04-29

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-Mo ,  CHOI, Hojin ,  KIM, Dohoon ,  KIM, Soyoung ,  HA, Nina ,  LIM, Hyojin ,  KO, Eunhee ,  YOON, Seongae ,  BAE, Daekwon

IPC分类号： C07D413/12 ,  A61K31/5377 ,  A61P35/00 ,  A61P29/00

CPC分类号： C07D231/56 ,  C07D207/08 ,  C07D207/10 ,  C07D209/08 ,  C07D209/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/52 ,  C07D213/40 ,  C07D213/74 ,  C07D213/75 ,  C07D215/12 ,  C07D239/26 ,  C07D239/42 ,  C07D265/30 ,  C07D295/215 ,  C07D309/08 ,  C07D309/10 ,  C07D317/58 ,  C07D319/18 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.